Selumetinib
- Generic Name
- Selumetinib
- Brand Names
- Koselugo
- Drug Type
- Small Molecule
- Chemical Formula
- C17H15BrClFN4O3
- CAS Number
- 606143-52-6
- Unique Ingredient Identifier
- 6UH91I579U
- Background
Activation of the Raf-MEK-ERK signaling pathway is known to be implemented in several types of malignancies, thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway.
...
- Indication
Although selumetinib has been investigated for the treatment of several types of cancer, it is currently only indicated for the treatment of neurofibromatosis type 1 (NF1) in patients β₯2 years who have symptomatic, inoperable plexiform neurofibromas (PN).
- Associated Conditions
- Neurofibromatosis, type 1 (von Recklinghausen's disease)
- Associated Therapies
- -
A Study of Selumetinib in Patients With Kaposi's Sarcoma
- First Posted Date
- 2012-12-19
- Last Posted Date
- 2019-02-20
- Target Recruit Count
- 19
- Registration Number
- NCT01752569
- Locations
- π¬π§
Brighton and Sussex University Hospitals, Brighton, United Kingdom
π¬π§Royal Free Hospital, London, United Kingdom
π¬π§Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2016-03-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 137
- Registration Number
- NCT01658943
- Locations
- πΊπΈ
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
πΊπΈKaiser Permanente-Riverside, Riverside, California, United States
πΊπΈProvidence Hospital-Southfield Cancer Center, Southfield, Michigan, United States
Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2014-06-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2
- Registration Number
- NCT01519427
- Locations
- πΊπΈ
Emory University, Atlanta, Georgia, United States
πΊπΈCancer Institute of New Jersey, New Brunswick, New Jersey, United States
πΊπΈVirginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States
Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 19
- Registration Number
- NCT01364051
- Locations
- πΊπΈ
Mayo Clinic in Florida, Jacksonville, Florida, United States
πΊπΈMayo Clinic in Rochester, Rochester, Minnesota, United States
Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2011-01-19
- Last Posted Date
- 2016-02-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 16
- Registration Number
- NCT01278615
- Locations
- πΊπΈ
Northwestern University, Chicago, Illinois, United States
πΊπΈUniversity of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
πΊπΈDecatur Memorial Hospital, Decatur, Illinois, United States
ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-11-17
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- University College, London
- Target Recruit Count
- 13
- Registration Number
- NCT01242605
- Locations
- π¬π§
University College London Hospital, London, United Kingdom
π¬π§Hammersmith Hospital, London, United Kingdom
π¬π§The Christie Hospital, Manchester, United Kingdom
Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
- First Posted Date
- 2010-10-18
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 46
- Registration Number
- NCT01222689
- Locations
- πΊπΈ
UCSF-Mount Zion, San Francisco, California, United States
πΊπΈOhio State University Medical Center, Columbus, Ohio, United States
Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2014-05-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 33
- Registration Number
- NCT01217450
- Locations
- πΊπΈ
National Cancer Institute Medicine Branch, Bethesda, Maryland, United States
πΊπΈWisconsin Clinical Cancer Center, Milwaukee, Wisconsin, United States
πΊπΈUniversity of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery
- First Posted Date
- 2010-09-21
- Last Posted Date
- 2015-10-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT01206140
- Locations
- πΊπΈ
City of Hope Comprehensive Cancer Center, Duarte, California, United States
πΊπΈTower Cancer Research Foundation, Beverly Hills, California, United States
πΊπΈUSC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
- Conditions
- Interventions
- First Posted Date
- 2010-07-20
- Last Posted Date
- 2014-05-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 4
- Registration Number
- NCT01166126
- Locations
- πΊπΈ
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.